Eiger Biopharmaceuticals (EIGR) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) from a sell rating to a hold rating in a research note issued to investors on Thursday.

According to Zacks, “Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. “

How to Become a New Pot Stock Millionaire

Several other analysts have also recently commented on the company. Oppenheimer set a $26.00 target price on Eiger Biopharmaceuticals and gave the company a buy rating in a research report on Tuesday, January 16th. Ladenburg Thalmann Financial Services initiated coverage on Eiger Biopharmaceuticals in a research report on Wednesday, January 3rd. They issued a buy rating and a $32.00 target price on the stock. Piper Jaffray Companies restated an overweight rating and issued a $17.00 target price (down from $35.00) on shares of Eiger Biopharmaceuticals in a research report on Tuesday, January 16th. ValuEngine upgraded Eiger Biopharmaceuticals from a sell rating to a hold rating in a research report on Sunday, December 31st. Finally, Wedbush lowered their target price on Eiger Biopharmaceuticals from $36.00 to $34.00 and set an outperform rating on the stock in a research report on Thursday. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Eiger Biopharmaceuticals has a consensus rating of Buy and an average price target of $27.25.

Shares of Eiger Biopharmaceuticals stock opened at $10.10 on Thursday. Eiger Biopharmaceuticals has a 1 year low of $6.10 and a 1 year high of $16.20. The company has a debt-to-equity ratio of 0.58, a current ratio of 5.85 and a quick ratio of 5.85. The company has a market capitalization of $106.32, a P/E ratio of -2.07 and a beta of 1.70.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its earnings results on Monday, March 12th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.09). equities analysts anticipate that Eiger Biopharmaceuticals will post -4.44 earnings per share for the current year.

Several hedge funds have recently modified their holdings of EIGR. Prosight Management LP acquired a new position in shares of Eiger Biopharmaceuticals during the 4th quarter valued at $9,469,000. Jennison Associates LLC acquired a new position in shares of Eiger Biopharmaceuticals during the 4th quarter valued at $8,430,000. Armistice Capital LLC acquired a new position in shares of Eiger Biopharmaceuticals during the 4th quarter valued at $5,357,000. Stonepine Capital Management LLC acquired a new position in shares of Eiger Biopharmaceuticals during the 4th quarter valued at $2,093,000. Finally, Sphera Funds Management LTD. increased its position in shares of Eiger Biopharmaceuticals by 35.0% during the 3rd quarter. Sphera Funds Management LTD. now owns 520,269 shares of the biotechnology company’s stock valued at $5,723,000 after purchasing an additional 134,968 shares during the period. Institutional investors own 68.96% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3299551/eiger-biopharmaceuticals-eigr-lifted-to-hold-at-zacks-investment-research.html.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.

Get a free copy of the Zacks research report on Eiger Biopharmaceuticals (EIGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

United States Lime & Minerals  Issues  Earnings Results
United States Lime & Minerals Issues Earnings Results
Zimmer Biomet  Announces  Earnings Results
Zimmer Biomet Announces Earnings Results
TriMas  Releases FY18 Earnings Guidance
TriMas Releases FY18 Earnings Guidance
Analyzing Liberty Tax Service  & Its Peers
Analyzing Liberty Tax Service & Its Peers
Contrasting Ituran  & Arrow Electronics
Contrasting Ituran & Arrow Electronics
Constellium  vs. Aqua Metals  Head-To-Head Survey
Constellium vs. Aqua Metals Head-To-Head Survey


© 2006-2018 Ticker Report. Google+.